1. Dopamine-loaded poly (butyl cyanoacrylate) nanoparticles reverse behavioral deficits in Parkinson's animal models
- Author
-
Seyed Mohammad Massood Hojjati, Koorosh Shahpasand, Fatemeh Hadi, Ashrafalsadat Hatamian Zarmi, Bahman Ebrahimi Hosseinzade, and Fatemeh Jahansooz
- Subjects
Parkinson's disease ,Dopamine ,Pharmaceutical Science ,Brain Structure and Function ,02 engineering and technology ,Neurological disorder ,Pharmacology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,In vivo ,Medicine ,Animals ,Humans ,Secretion ,Drug Carriers ,business.industry ,Brain ,Parkinson Disease ,Enbucrilate ,021001 nanoscience & nanotechnology ,medicine.disease ,Disease Models, Animal ,chemistry ,Models, Animal ,Butyl cyanoacrylate ,Nanoparticles ,Delivery system ,0210 nano-technology ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Aim: Parkinson's disease (PD) is a neurological disorder resulting from decreased dopamine (DA) secretion in the brain, which reflects impaired motor function. Thus, a drug-delivery system for releasing DA into the brain would be of crucial importance. Materials & methods: We herein examined the in vivo drug efficiency of novel poly-butyl-cyanoacrylate nanoparticles loaded with DA (DA-PBCA NPs). Results & conclusion: The NPs were able to pass through the blood–brain barrier and improve brain structure and function in the PD animal models. Moreover, we found a reduced α-synucleinopathy in the animal model brains after the NPs administration. Thus, the NPs seem to be a reliable DA delivery system for treating PD patients.
- Published
- 2020